NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEOGet Rating) have received a consensus rating of “Hold” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $18.70.

A number of analysts have commented on the stock. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a report on Friday, October 28th. Cowen cut their price objective on shares of NeoGenomics to $17.00 in a report on Tuesday, November 15th. Morgan Stanley dropped their price target on shares of NeoGenomics from $18.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 9th. StockNews.com cut shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Saturday, November 19th. Finally, SVB Leerink increased their price target on shares of NeoGenomics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, November 9th.

NeoGenomics Stock Down 3.3 %

NEO opened at $11.55 on Wednesday. NeoGenomics has a twelve month low of $6.00 and a twelve month high of $23.78. The company has a quick ratio of 6.82, a current ratio of 7.10 and a debt-to-equity ratio of 0.53. The company has a 50-day moving average price of $10.52 and a 200 day moving average price of $9.76. The company has a market cap of $1.46 billion, a PE ratio of -8.75 and a beta of 1.06.

NeoGenomics (NASDAQ:NEOGet Rating) last released its quarterly earnings results on Tuesday, November 8th. The medical research company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The firm had revenue of $128.78 million during the quarter, compared to the consensus estimate of $122.55 million. NeoGenomics had a negative net margin of 32.88% and a negative return on equity of 9.46%. Sell-side analysts expect that NeoGenomics will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors boosted its position in shares of NeoGenomics by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock worth $47,000 after purchasing an additional 844 shares during the period. Public Sector Pension Investment Board boosted its position in shares of NeoGenomics by 0.5% during the 2nd quarter. Public Sector Pension Investment Board now owns 230,946 shares of the medical research company’s stock worth $1,882,000 after purchasing an additional 1,152 shares during the period. Private Advisor Group LLC boosted its position in shares of NeoGenomics by 9.6% during the 2nd quarter. Private Advisor Group LLC now owns 15,424 shares of the medical research company’s stock worth $126,000 after purchasing an additional 1,355 shares during the period. American International Group Inc. boosted its position in shares of NeoGenomics by 2.5% during the 2nd quarter. American International Group Inc. now owns 67,325 shares of the medical research company’s stock worth $549,000 after purchasing an additional 1,623 shares during the period. Finally, Gamco Investors INC. ET AL boosted its position in shares of NeoGenomics by 5.8% during the 1st quarter. Gamco Investors INC. ET AL now owns 31,210 shares of the medical research company’s stock worth $379,000 after purchasing an additional 1,700 shares during the period. Hedge funds and other institutional investors own 88.15% of the company’s stock.

NeoGenomics Company Profile

(Get Rating)

NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.

Further Reading

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.